On November 5, the day the Second CIIE kicked off, CDHT and the exhibitor AstraZeneca signed the MOU on the Strategic Cooperation of Western China Headquarters of AstraZeneca, symbolizing that another multinational pharmaceutical giant has been settled in CDHT, and its innovative imported drugs will be introduced from Chengdu to domestic markets.
AstraZeneca headquartered in London is a world-renowned multinational pharmaceutical corporation. In the list of Fortune Global 500 in 2017, it ranked the 470th; and in 2018, its operation revenue reached USD 22 billion. Since its entering into Chinese market in 1993, AstraZeneca has been one of the multinational pharmaceutical enterprises seeing the fastest growth in China that registered a revenue here of USD 3.76 billion in 2018.
It is reported that the Western China Headquarters of AstraZeneca positioned as a regional headquarters will be among the 4 major headquarters of AstraZeneca in China, which is designed to handle the operation affairs of the headquarters as a whole, as well as implement projects involving AstraZeneca Business Innovation Center and Industrial Incubator. The former project will center on the integration of diagnosis and treatment. AstraZeneca capable of demonstration, supporting, research, promotion and other functions will provide a platform to integrate outstanding enterprises and solutions at the upstream and downstream of the industrial chain.
AstraZeneca Logistics Center China
Leveraging the advantages of AstraZeneca worldwide, the Industrial Incubator will bring in and incubate excellent projects of countries along the “Belt and Road”, as well as offer professional assistance and industrial guarantee for those incubated projects. Meanwhile, AstraZeneca will resort to the superiority of Chengdu as a strategic node along the “Belt and Road” to settle its innovative imported varieties in CDHT. In the days to come, part of its imported products will be marketed nationwide from Chengdu.
AstraZeneca Supply Base (Taizhou)
A principal of AstraZeneca expressed that AstraZeneca sees the establishment of the Western China Headquarters as a move to develop Sichuan and CDHT into one of the significant strategic bases in China. Next, the company will take advantage of Chengdu as a strategic node along the “Belt and Road”, utilize resources like Chengdu Global Biomedical Supply Chain Service Center, and make the best of National (Chengdu) Biomedical R&D and Innovation Industrial Base, as well as the abundant personnel and clinical resources to introduce more innovative products, and enlarge the coverage of products and services to common families, making the high-end medical resources available to more patients.
AstraZeneca Supply Center (Wuxi)
CDHT, where Western China Headquarters of AstraZeneca and innovative imported varieties were settled in this time, represents the cluster of the biomedical industry in Middle-Western China and the main field for Chengdu to advance its bio-industry. It is the National Industrial Base of Biomedicine R&D and Innovation, among the first batch of national pharmaceutical export bases, National Industrial Base of Modern TCM Technology, National Hi-tech Industrial Base of Biomedical Materials and Medical Equipment, and the pilot demonstration base for the achievements transfer & transformation of national key and new medicines development and major technological projects.
In 2019 Comprehensive Competitiveness Ranking of National Biomedical Industrial Parks, CDHT was ranked the 6th.
Chengdu Hi-tech Industrial Development Zone (CDHT)
A principal of CDHT introduced that this cooperation will be beneficial for Sichuan and Chengdu to foster the global biomedicine supply chain service center. CDHT, taking the construction of national demonstration base of key and new drugs development as an opportunity, is sparing no effort to build the bio-industry ecosphere, accelerating the erection of the bio-industrial functional zone where enjoys distinctive industrial characteristics, complete industrial ecology, professional supporting functions, scientific spatial layout, prominent park culture and innovative system & mechanism, as well as speeding up to establish the national high-quality development demonstration area and world-leading hi-tech park.
Tianfu Life Science Park (Phase II)
Park WeiChart